Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome

International Journal of Hematology

Volumn 72, Issue 4, 2000, Pages 517-519

  Yamamoto, Kazuhiko ^a   Niiya, Kenji ^a   Shigematu, Terunobu ^a   Kiguchi, Toru ^a   Takenaka, Katsuto ^a   Shinagawa, Katsushi ^a   Ishimaru, Fumihiko ^a   Ikeda, Kazuma ^a   Shima, Midori ^b   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

DIC; Factor VIII inhibitor; Hemophilia A; Septic shock syndrome; Septicemia; Staphylococcus aureus

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLOOD; CASE REPORT; CLASSIFICATION; HEMOPHILIA A; HUMAN; IMMUNOLOGY; MALE; MICROBIOLOGY; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION;

ADULT; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS;

EID: 0034571404     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Clifton GL, Allen S, Barrodale P, et al. A phase II study of moderate hypothermia in severe brain injury. J Neurotrauma. 1993; 10:263-271.
2. Cederbaum AI, Blatt PM, Roberts HR. Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med. 1976;84:683-687.
3. Kamisue S, Shima M, Nishimura T, et al. Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA. Br J Haematol. 1994;86:106-111.
4. Biggs R, Austen DE, Denson KW, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII, I: Antibodies which have second-order concentration graphs. Br J Haematol. 1972;23:125-135.
5. Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group. Int J Hematol. 1995;62: 35-43.
6. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med. 1984;144:541-545.
7. Drake TA, Pang M. Staphylococcus aureus induces tissue factor expression in cultured human cardiac valve endothelium. J Infect Dis. 1988:157:749-756.
8. Kessler CM, Nussbaum E, Tuazon CU. Disseminated intravascular coagulation associated with Staphylococcus aureus septicemia is mediated by peptidoglycan-induced platelet aggregation. J Infect Dis. 1991:164:101-107.
9. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood. 1997; 89:4393-4401.
10. Balk R, Emerson T, Fourrier F, et al. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost. 1998;24:183-194.
11. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45:200-203.
12. Biggs R, Austen DE, Denson KW, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII, II: Antibodies which give complex concentration graphs. Br J Haematol. 1972;23:137-155.
13. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594-598.